Pilot Screening of Cell-Free mtDNA in NIPT: Quality Control, Variant Calling, and Haplogroup Determination

Genes (Basel). 2021 May 14;12(5):743. doi: 10.3390/genes12050743.

Abstract

Clinical tests based on whole-genome sequencing are generally focused on a single task approach, testing one or several parameters, although whole-genome sequencing (WGS) provides us with large data sets that can be used for many supportive analyses. In spite of low genome coverage, data of WGS-based non-invasive prenatal testing (NIPT) contain fully sequenced mitochondrial DNA (mtDNA). This mtDNA can be used for variant calling, ancestry analysis, population studies and other approaches that extend NIPT functionality. In this study, we analyse mtDNA pool from 645 cell-free DNA (cfDNA) samples of pregnant women from different regions of Russia, explore the effects of transportation and storing conditions on mtDNA content, analyse effects, frequency and location of mitochondrial variants called from samples and perform haplogroup analysis, revealing the most common mitochondrial superclades. We have shown that, despite the relatively low sequencing depth of unamplified mtDNA from cfDNA samples, the mtDNA analysis in these samples is still an informative instrument suitable for research and screening purposes.

Keywords: ClinVar; NIPT; SNPs; breast cancer; cfDNA; foetal fraction; mitochondrial diseases; mitochondrial variants; mtDNA; mtDNA haplogroups; population studies; transportation.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cell-Free Nucleic Acids / genetics*
  • DNA, Mitochondrial / genetics*
  • Female
  • Haplotypes / genetics*
  • Humans
  • Mitochondria / genetics*
  • Noninvasive Prenatal Testing / methods
  • Pilot Projects
  • Polymorphism, Single Nucleotide / genetics*
  • Pregnancy
  • Quality Control
  • Russia
  • Whole Genome Sequencing / methods

Substances

  • Cell-Free Nucleic Acids
  • DNA, Mitochondrial